MARKET

OCUP

OCUP

Ocuphire Pharma Inc
NASDAQ
1.650
-0.030
-1.79%
After Hours: 1.649 -0.001 -0.05% 18:07 06/14 EDT
OPEN
1.660
PREV CLOSE
1.680
HIGH
1.710
LOW
1.650
VOLUME
53.44K
TURNOVER
0
52 WEEK HIGH
4.580
52 WEEK LOW
1.500
MARKET CAP
42.77M
P/E (TTM)
-3.3902
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at OCUP last week (0603-0607)?
Weekly Report · 4d ago
Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June
Clinical updates on the Company's lead candidate APX3330 for diabetic retinopathy will be featured in upcoming presentations. Ocuphire Pharma, Inc. Is a clinical-stage biopharmaceutical company focused on developing small molecule therapies for retinal and refractive eye disorders.
Barchart · 06/06 06:57
Weekly Report: what happened at OCUP last week (0527-0531)?
Weekly Report · 06/03 09:57
Weekly Report: what happened at OCUP last week (0520-0524)?
Weekly Report · 05/27 09:59
Duos Technologies And 2 Other Stocks Under $3 Insiders Are Buying
Insider transactions for penny stocks indicate confidence or concern about the company's prospects. Ocuphire Pharma, Inc. CEO George Magrath acquired a total of 5,000 shares at an average price of $. Bespoke Extracts, Inc CEO Michael Feinsod bought 2,000Shares of the company.
Benzinga · 05/22 11:35
Weekly Report: what happened at OCUP last week (0513-0517)?
Weekly Report · 05/20 09:56
Ocuphire Pharma Is Maintained at Buy by Canaccord Genuity
Dow Jones · 05/13 16:50
Ocuphire Pharma Price Target Cut to $18.00/Share From $22.00 by Canaccord Genuity
Dow Jones · 05/13 16:50
More
About OCUP
Ocuphire Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. The Company’s lead retinal product candidate, APX3330, is a small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein). Ref1 is a regulator of transcription factors such as HIF-1α and NF-B. The Inhibiting REF-1 reduces levels of vascular endothelial growth factor (VEGF) and inflammatory cytokines which are known to play key roles in ocular angiogenesis and inflammation. APX3330 is an oral tablet to be administered twice per day for the treatment of DR. The Company’s pipeline candidates include APX2009 and APX2014. The Company is initially pursuing APX3330 for the DR indication as first-line therapy and may explore opportunities for clinical benefit as monotherapy or adjunctive therapy for other retinal indications such as DME, wAMD, and GA.

Webull offers Ocuphire Pharma Inc stock information, including NASDAQ: OCUP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCUP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OCUP stock methods without spending real money on the virtual paper trading platform.